0001104659-21-031160.txt : 20210303 0001104659-21-031160.hdr.sgml : 20210303 20210303084721 ACCESSION NUMBER: 0001104659-21-031160 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210303 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210303 DATE AS OF CHANGE: 20210303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OMEGA HEALTHCARE INVESTORS INC CENTRAL INDEX KEY: 0000888491 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 383041398 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11316 FILM NUMBER: 21707334 BUSINESS ADDRESS: STREET 1: 303 INTERNATIONAL CIRCLE, STREET 2: SUITE 200 CITY: HUNT VALLEY STATE: MD ZIP: 21030 BUSINESS PHONE: 410-427-1700 MAIL ADDRESS: STREET 1: 303 INTERNATIONAL CIRCLE, STREET 2: SUITE 200 CITY: HUNT VALLEY STATE: MD ZIP: 21030 8-K 1 tm218559d1_8k.htm FORM 8-K
0000888491 false 0000888491 2021-03-03 2021-03-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 3, 2021

 

OMEGA HEALTHCARE INVESTORS, INC.

(Exact name of registrant as specified in its charter)

 

Maryland 1-11316 38-3041398
(Omega Healthcare Investors, Inc.) (Omega Healthcare Investors, Inc.) (Omega Healthcare Investors, Inc.)

  

303 International Circle

Suite 200

Hunt Valley, Maryland 21030

(Address of principal executive offices / Zip Code)

 

(410) 427-1700

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act.

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

     
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $.10 par value OHI New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 8.01 Other Events.

 

On March 3, 2021, Omega Healthcare Investors, Inc., a Maryland corporation (“Omega”), announced that it commenced a tender offer to purchase for cash up to $250,000,000 aggregate principal amount of Omega’s 4.375% Senior Notes due 2023. The tender offer is being made exclusively pursuant to an offer to purchase dated March 3, 2021, which sets forth the terms and conditions of the tender offer.

 

A copy of the press release announcing the tender offer is attached hereto as Exhibit 99.1 and is incorporated in this Item 8.01 by reference.

 

Statements in this Current Report on Form 8-K (including the Exhibits hereto) that are not historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding Omega’s and its officers’ intent, belief or expectation identified by its use of terms and phrases such as “may,” “will,” “project,” “expect,” “believe,” “intend,” “anticipate,” “seek,” “target,” “forecast,” “plan,” “potential,” “estimate,” “could,” “would,” “should” and other comparable and derivative terms and phrases or the negatives thereof, including references to assumptions and forecasts of future results. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors which may cause the actual results to differ materially from those anticipated at the time the forward-looking statements are made. These risks include those risks and uncertainties associated with Omega’s business described in its Annual Report on Form 10-K filed on February 22, 2021 and its subsequent filings with the Securities and Exchange Commission. Although Omega believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, Omega can give no assurance that the expectations will be attained or that any deviation will not be material. Except as required by law, Omega does not undertake, and hereby disclaims, any obligation to update any forward-looking statement which speak only as of the date on which they are made.

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits. The following exhibits are being filed herewith:

 

No.   Description
99.1   Press Release, dated March 3, 2021
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  OMEGA HEALTHCARE INVESTORS, INC. 
       
       
Dated: March 3, 2021 By:  /s/ Gail D. Makode 
     Gail D. Makode 
     Chief Legal Officer, General Counsel and Secretary 

 

 

 

 EX-99.1 2 tm218559d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

303 International Circle

Suite 200

Hunt Valley, MD 21030

P: 410.427.1700

F: 410.427.8800

  

PRESS RELEASE – FOR IMMEDIATE RELEASE

 

Omega Healthcare Announces Tender Offer for Outstanding
4.375% Notes due 2023

 

HUNT VALLEY, MARYLAND – March 3, 2021 – Omega Healthcare Investors, Inc. (NYSE: OHI) (“Omega”) today announced that it commenced a tender offer (the “Tender Offer”) to purchase for cash up to an aggregate principal amount of $250 million (the “Aggregate Maximum Tender Amount”) of its 4.375% Senior Notes due 2023 (the “Notes”).

 

Title of Note CUSIP Number Principal
Amount
Outstanding		 Aggregate
Maximum
Tender
Amount		 U.S.
Treasury
Reference
Security		 Bloomberg
Reference
Page		 Fixed
Spread		 Early
Tender
Premium
(1)(2)		 Applicable
Par Call Date
4.375%
Senior Notes
due 2023		 681936BJ8 $700
million		 $250 million 1.65%
UST due
5/31/2023		 FIT5 +50 bps $30 June 1, 2023

 

(1)Per $1,000 principal amount.

(2)The Total Consideration for Notes validly tendered prior to or at the Early Tender Time (as defined below) and accepted for purchase is calculated using the Fixed Spread (as defined below) and is inclusive of the Early Tender Premium.

 

The Tender Offer consists of an offer to purchase the Notes for cash, on the terms and conditions set forth in the offer to purchase, dated March 3, 2021 (as the same may be amended or supplemented, the “Offer to Purchase”). Subject to the Aggregate Maximum Tender Amount, proration (if applicable) and the satisfaction or waiver of the conditions to the Tender Offer, including a financing condition, Omega will accept for purchase on the Early Settlement Date, if any, or the Final Settlement Date (each as defined in the Offer to Purchase), as applicable, Notes validly tendered in the Tender Offer.

 

Notes validly tendered at or prior to the Early Tender Time will be accepted for purchase in priority to other Notes validly tendered after the Early Tender Time. Accordingly, if the Aggregate Maximum Tender Amount is reached in respect of tenders of Notes made at or prior to the Early Tender Time, no Notes that are tendered after the Early Tender Time will be accepted for purchase unless the Aggregate Maximum Tender Amount is increased by Omega, in its sole discretion, subject to proration.

 

The Tender Offer will expire at 11:59 p.m., New York City Time, at the end of March 30, 2021, or any other date and time to which Omega extends the Tender Offer (such time and date, as it may be extended, the “Expiration Time”), unless the Tender Offer is earlier terminated. Holders of the Notes must validly tender and not validly withdraw the Notes prior to or at 5:00 pm, New York City Time, on March 16, 2021 (such date and time, as it may be extended, the “Early Tender Time”), to be eligible to receive the Total Consideration, which is inclusive of an amount in cash equal to the amount set forth in the table above under the heading “Early Tender Premium” (the “Early Tender Premium”), plus Accrued Interest (as defined below). Holders of the Notes who validly tender their Notes after the Early Tender Time but prior to or at the Expiration Time will be eligible to receive an amount equal to the Total Consideration minus the Early Tender Premium plus Accrued Interest.

 

 

 

 

Subject to applicable law, Omega may increase or decrease the Aggregate Maximum Tender Amount in its sole discretion. Subject to applicable law, Omega may increase or decrease the Aggregate Maximum Tender Amount without extending the Withdrawal Deadline (as defined below).

 

The Notes may be validly withdrawn at any time prior to, but not after, 5:00 pm, New York City Time, on March 16, 2021 (such date and time, as it may be extended, the “Withdrawal Deadline”). Subject to applicable law, Omega may increase or decrease the Aggregate Maximum Tender Amount without extending the Withdrawal Deadline.

 

The “Total Consideration” for each $1,000 principal amount of Notes validly tendered and accepted for purchase pursuant to the Tender Offer will be determined in the manner described in the Offer to Purchase by reference to the fixed spread for the Notes specified in the table above plus the yield based on the bid-side price of the U.S. Treasury Reference Security specified in the table above at 10:00 a.m., New York City Time, on March 17, 2021, unless extended or the Tender Offer is earlier terminated.

 

Except as set forth below, payment for the Notes that are validly tendered prior to or at the Expiration Time will, if not previously paid for on an earlier settlement date, if applicable, be made on a date promptly following the Expiration Time, which is currently anticipated to be March 30, 2021, the second business day after the Expiration Time. Omega reserves the right, in its sole discretion, to make payment for Notes that are validly tendered prior to or at the Early Tender Time on an earlier settlement date, which, if Omega so elects, is currently anticipated to be March 18, 2021, provided that the conditions to the Tender Offer have been satisfied or waived.

 

Holders of the Notes will also receive accrued and unpaid interest on their Notes validly tendered and accepted for purchase from the last interest payment date up to, but not including, the applicable settlement date (“Accrued Interest”).

 

The Tender Offer is subject to the satisfaction or waiver of certain conditions, including a financing condition, as more fully set forth in the Offer to Purchase. The Tender Offer is not subject to minimum tender conditions.

 

Information Relating to the Tender Offer

 

The Offer for Purchase is being distributed to holders beginning today. Credit Agricole Securities (USA) Inc. is serving as the Lead Dealer Manager for the Tender Offer. Investors with questions regarding the Tender Offer may contact the Lead Dealer Manager by phone at (866) 807-6030 (Toll Free) or (212) 261-7802 (Collect), by email at us.liabilitymanagement@ca-cib.com, or by mail addressed to Credit Agricole Securities (USA) Inc. at 1301 Avenue of the Americas, 17th Floor, New York, NY 10019, Attention: Debt Capital Markets/Liability Management.

 

None of Omega or its affiliates, their respective boards of directors, the dealer managers, the tender and information agent or the trustee with respect to the Notes is making any recommendation as to whether holders should tender any Notes in response to the Tender Offer, and neither Omega nor any such other person has authorized any person to make any such recommendation. Holders must make their own decision as to whether to tender any of their Notes, and, if so, the principal amount of Notes to tender.

 

This press release is for informational purposes only and is not an offer to buy, or the solicitation of an offer to sell, any of the Notes and the Tender Offer does not constitute an offer to buy or the solicitation of an offer to sell the Notes in any jurisdiction or in any circumstances in which such offer or solicitation are unlawful. The full details of the Tender Offer, including complete instructions on how to tender the Notes, are included in the Offer to Purchase. Holders are strongly encouraged to carefully read the Offer to Purchase, including materials incorporated by reference therein, because they will contain important information. The Offer to Purchase may be downloaded from Global Bondholder Services Corporation’s website at https://www.gbsc-usa.com/omega/ or obtained from Global Bondholder Services Corporation, free of charge, by calling toll free at (866) 470-4300 (bankers and brokers can call collect at (212) 430-3774).

 

 

 

 

About Omega

 

Omega is a real estate investment trust that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities. Its portfolio of assets is operated by a diverse group of healthcare companies, predominantly in a triple-net lease structure. The assets span all regions within the United States, as well as in the United Kingdom. More information on Omega is available at www.omegahealthcare.com.

 

Forward-Looking Statements

 

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding Omega’s or its tenants’, operators’, borrowers’ or managers’ expected future financial condition, results of operations, cash flows, funds from operations, dividends and dividend plans, financing opportunities and plans, capital markets transactions, business strategy, budgets, projected costs, operating metrics, capital expenditures, competitive positions, acquisitions, investment opportunities, dispositions, facility transitions, growth opportunities, continued qualification as a real estate investment trust, plans and objectives of management for future operations and statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions are forward-looking statements. These forward-looking statements are inherently uncertain, and actual results may differ from Omega’s expectations.

 

Omega’s actual results may differ materially from those reflected in such forward-looking statements as a result of a variety of factors, including, among other things: (i) uncertainties relating to the business operations of the operators of Omega’s properties, including those relating to reimbursement by third-party payors, regulatory matters and occupancy levels; (ii) the impact of novel coronavirus (“COVID-19”) on our business and the business of our operators, including without limitation, the extent and duration of the COVID-19 pandemic, increased costs experienced by operators of skilled nursing facilities and assisted living facilities in connection therewith, and the extent to which continued government support may be available to operators to offset such costs and the conditions related thereto; (iii) the ability of our operators to comply with the terms and conditions pursuant to which government support may be available; (iv) the risk Omega may not complete this offering in a timely fashion or at all, and (v) those risks and uncertainties associated with Omega’s business described in its Annual Report on Form 10-K filed on February 28, 2020 and its subsequent filings with the Securities and Exchange Commission. Although Omega believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, Omega can give no assurance that the expectations will be attained or that any deviation will not be material. We caution you that the foregoing list of important factors may not contain all of the material factors that are important to you. Accordingly, readers should not place undue reliance on those statements. All forward-looking statements are based upon information available to us on the date of this release. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

 

Contact

 

Bob Stephenson, CFO, or Matthew Gourmand, SVP Corporate Strategy & Investor Relations, at (410) 427-1700.

 

 

 

 EX-101.SCH 3 ohi-20210303.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ohi-20210303_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ohi-20210303_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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end XML 7 tm218559d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000888491 2021-03-03 2021-03-03 iso4217:USD shares iso4217:USD shares 0000888491 false 8-K 2021-03-03 OMEGA HEALTHCARE INVESTORS, INC. MD 1-11316 38-3041398 303 International Circle Suite 200 Hunt Valley MD 21030 410 427-1700 false false false false Common Stock, $.10 par value OHI NYSE false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover
Mar. 03, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 03, 2021
Entity File Number 1-11316
Entity Registrant Name OMEGA HEALTHCARE INVESTORS, INC.
Entity Central Index Key 0000888491
Entity Tax Identification Number 38-3041398
Entity Incorporation, State or Country Code MD
Entity Address, Address Line One 303 International Circle
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Hunt Valley
Entity Address, State or Province MD
Entity Address, Postal Zip Code 21030
City Area Code 410
Local Phone Number 427-1700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $.10 par value
Trading Symbol OHI
Security Exchange Name NYSE
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://omegahealthcare.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm218559d1_8k.htm ohi-20210303.xsd ohi-20210303_lab.xml ohi-20210303_pre.xml tm218559d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm218559d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm218559d1_8k.htm" ] }, "labelLink": { "local": [ "ohi-20210303_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "ohi-20210303_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "ohi-20210303.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ohi", "nsuri": "http://omegahealthcare.com/20210303", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm218559d1_8k.htm", "contextRef": "From2021-03-03to2021-03-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://omegahealthcare.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm218559d1_8k.htm", "contextRef": "From2021-03-03to2021-03-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-031160-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-031160-xbrl.zip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end